The US Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type ​2 ...

The FDA has approved a once-weekly basal insulin to control glucose levels for adults with type 2 diabetes, Eli Lilly ...

Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora ...

Approval marks the second once-weekly basal insulin for this population ...

The FDA just handed Eli Lilly a new diabetes approval, but the real debate is whether a once-weekly insulin needle moves the ...

Eli Lilly and Company LLY secured FDA approval for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin to treat ...

Dr. Marie McDonnell, the director of the Brigham Diabetes Program at Brigham and Women’s Hospital in Boston, told TODAY that basal insulin is a long-acting insulin therapy that helps the body process ...

The FDA has approved the once-weekly injectable basal insulin drug insulin efsitora alfa-gobe (Onswik, Eli Lilly) for use as ...

People with type 2 diabetes (T2D) who began using continuous glucose monitoring (CGM) while receiving basal insulin had a 44% ...

Dexcom said Smart Basal works to dial in a personalized background insulin dose by checking all of a user's CGM readings, not a fasting blood sugar check. (Dexcom) Dexcom has obtained an FDA clearance ...

Please provide your email address to receive an email when new articles are posted on . Change in HbA1c and hypoglycemia rates were similar between once-weekly basal insulin and once-daily insulin ...

The FDA approved Onswik, a once-weekly basal insulin for adults with type 2 diabetes. Here's how it works, who it's for and ...